2020
DOI: 10.1002/adhm.202070035
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Resevoirs: Implantable Therapeutic Reservoir Systems for Diverse Clinical Applications in Large Animal Models (Adv. Healthcare Mater. 11/2020)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…A sensor-enabled macroencapsulation device was manufactured following some of the techniques previously described, [57][58][59] as shown in Figure S3, Supporting Information. This device was composed of two layers of 6 mil thermoplastic polyurethane (TPU, American Polyfilm Inc) and with a capacity of 5 mL.…”
Section: Macroencapsulation Device Manufacturingmentioning
confidence: 99%
“…A sensor-enabled macroencapsulation device was manufactured following some of the techniques previously described, [57][58][59] as shown in Figure S3, Supporting Information. This device was composed of two layers of 6 mil thermoplastic polyurethane (TPU, American Polyfilm Inc) and with a capacity of 5 mL.…”
Section: Macroencapsulation Device Manufacturingmentioning
confidence: 99%
“…[ 64 , 84 ] Intramuscular implant sites are promising in this regard as they a have higher affinity for neovascularization, [ 85 ] and can be accessed minimally invasively with specialized delivery devices. [ 86 ] The intraperitoneal space has also been explored as a potential site of implantation, as the peritoneal cavity can accommodate large volumes of cells that are required to reverse T1D in patients. However, accessing this space can result in numerous complications associated with intra‐abdominal procedures.…”
Section: Sustaining Sc‐islet Viability In a Temporally Dynamic Environmentmentioning
confidence: 99%
“…Hence, multiple islet infusions are often required to reverse insulin dependence. [ 186 ] Many of the commercially available [ 5 , 80 ] and research stage devices [ 86 , 176 , 187 ] have incorporated features (tubing and self‐sealing subcutaneous or transcutaneous ports) to enable the repeated delivery of cell cargo. This design consideration is particularly relevant to allow dosing and cargo adjustment if one thinks about future incorporation of continuous sensing of implant function.…”
Section: Minimizing Foreign Body Responsementioning
confidence: 99%